RAPID ANTIGEN TEST AND MOBILE NAVICA APP DESIGNED TO HELP RESTORE A BIT MORE CONFIDENCE IN DAILY LIFE.
BinaxNOW Ag is now available over-the-counter, bringing accessible COVID-19 rapid self-testing to the masses.
In this critical moment in the pandemic, testing is fundamental in our ability to help facilitate a return to work, school and life with a bit more confidence. BinaxNOW™ is a fast, reliable, affordable and portable rapid test that Abbott will produce at mass scale to greatly expand access to testing to people who need it. We ship tens of millions of tests each month and continue to ramp production.
We've paired this 15-minute, easy-to-use test with a mobile app, called NAVICA™, which works like a secure digital "health pass" that can be scanned to enter organizations and other places where people gather. This combination is life-changing technology that will attack the pandemic on critical fronts – speed, simplicity, affordability, access and reliability.
For U.S. residents, sign up to get notified when testing is available in your area.
Get the app before your first test.
Click here for product information on the test that allows rapid results in the safety and convenience of your home.
For professional use, click here for product information on the BinaxNOW COVID-19 Ag Card and the NAVICA App.
Our BinaxNOW COVID test can be used at home through guided online service.
With the prospect of kids returning to school, we’re here to help.
With verified results, app's QR code can be digital pass for places people gather.
Comprehensive testing solution to help you feel more confident about your health.
Fast. Affordable. Portable.
What is it, where you can get it and other answers to help you get started.
BinaxNOW and NAVICA are strong tools to help us get back to daily life.
Explaining the trade-offs between rapid antigen tests vs. lab-based tests.
Expert says a test with an app improves efficiency of communicating results.
Abbott has been a global leader in infectious-disease testing for many decades. We’ve been dedicated to meeting health needs since long before this pandemic, and we will be for long after. The BinaxNOW COVID-19 Ag Card provides a fast and reliable tool for detecting active coronavirus infections.
BinaxNOW is a rapid test that detects COVID-19 antigens (the proteins that make up the virus) to help identify someone is currently infected. It is easy-to-use, provides fast results and can help healthcare professionals quickly identify infectious people so they can take measures to help prevent the spread of the disease to others.
Everything needed to perform the BinaxNOW antigen test is included in a credit-card-sized kit, which lets authorized healthcare providers (such as a school nurse) test quickly and easily.
The BinaxNOW test has been authorized by the U.S. Food and Drug Administration through its Emergency Use Authorization process and is intended to identify antigen from SARS-CoV-2 in a nasal swab. For complete information on the BinaxNOW test, visit https://www.fda.gov/media/141570/download.
Antigens, like the ones found in COVID-19, are proteins of a virus that can be detected during the infection cycle. Antigen tests can indicate high quantities of this protein in an active infection.
Because rapid antigen tests can help identify people when they are infectious and at the highest risk of spreading the disease, they can be a powerful tool, in addition to following other measures such as wearing a mask, hand-washing and social distancing.
Testing, along with other important measures such as hand-washing, social distancing and wearing masks, is fundamental to helping slow the spread of COVID-19.
Through BinaxNOW rapid antigen testing (and where applicable, our NAVICA app), schools will be able to more quickly identify those who are infectious and get them into quarantine per their protocols.
BinaxNOW is administered by a healthcare provider, such as a school nurse or a nurse practitioner or pharmacist at a retail pharmacy. Administering the test is a simple and quick process.
BinaxNOW is administered as follows:
NAVICA is a first-of-its-kind app, available at no charge, that is designed to complement the BinaxNOW test. If available, the NAVICA app communicates test results and allows people who test negative to display a temporary digital “pass” that is renewed each time a person is tested. The NAVICA app can be downloaded from the App Store (Apple) and GooglePlay (Android). For more information on NAVICA, visit, https://www.abbott.com/BinaxNOW-Test-NAVICA-App/NAVICA-FAQ.html.
Protocols will vary by school. A negative BinaxNOW result means the test did not detect COVID-19 antigens that indicate someone is currently sick and potentially infectious. As with any diagnostic test, the result is based on a person’s health condition at the time of testing, and a negative result one day does not mean that a person might not become infectious (positive) later on.
If using the NAVICA app to display testing results, the digital pass stored in the app is designed to be temporary and expires after 7 days.
Protocols for notification of a positive result will vary by school.
If using the NAVICA app, after a positive test, users will also get a message that includes CDC guidelines recommending that they quarantine and see a doctor.
As protocols will vary by school, please reach out to your school administration.
Not having access to a mobile device shouldn’t be a barrier to attending school. While protocols will vary by school, common-sense methods can be used in lieu of the NAVICA digital pass, such as matching negative results to attendance records, offering students individual paper passes, or maintaining a paper or digital database of students and faculty who test negative.
Protocols around testing will be determined by school.
Results are available in 15 minutes for the healthcare provider.
Unlike a nasopharyngeal swab that requires the healthcare provider to insert the swab in the upper nasal cavity, these samples are taken by a nasal swab in the lower nasal cavity.
This will depend on your school's protocol. Please contact an administrator for this information.
The federal government purchased the first 150 million Abbott BinaxNOW diagnostic tests on August 27, 2020, for distribution nationwide. Schools are developing testing protocols based on supply of testing and will determine how to administer their testing program based on testing allotment and state guidance.
Healthcare providers in all settings are required to report COVID-19 test information and results to public health authorities, regardless of whether they use the NAVICA app. More information on the reporting requirements for COVID-19 testing is available on the Centers for Disease Control and Prevention (CDC'’s website at: https://www.cdc.gov/coronavirus/2019-ncov/lab/reporting-lab-data.html
The BinaxNOW™ COVID-19 Ag Card EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories. The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
The BinaxNOW™ COVID-19 Ag Card Home Test has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization. The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.